Latest Breaking News On - நிறுவனம் மேற்பார்வை பலகை - Page 5 : comparemela.com

Successful Closing of the Financial Restructuring of Europcar Mobility Group1: the Group Opens a New Chapter in Its History, With Renewed Ambitions

Successful Closing of the Financial Restructuring of Europcar Mobility Group1: the Group Opens a New Chapter in Its History, With Renewed Ambitions Significantly reduced corporate debt: from €2.010m to €910m New Governance, with Mr. Alexandre de Juniac as Chairman of the board of directors Regulatory News: Europcar Mobility Group 2 (Paris:EUCAR) announces today the finalization of its balance sheet restructuring, thanks to the successful completion of the final steps of the accelerated financial safeguard plan approved by the Paris Commercial Court on February 3 rd, 2021. This will enable the Group to accelerate the implementation of Connect , its strategic roadmap, while actively preparing for the progressive recovery of domestic and international travel.

United statesNew zealandFrance generalSimon franksVincent vevaudVirginie fauvelMartine gerowCaroline parotCaroline cohenAnchorage capital groupMobility service companyParis commercial court onEuropcar mobility groupEffective restructuring date of the companyCompany supervisory boardAlexandre de juniac

Витренко объяснил, почему хочет уволить своего экс-соратника Коболева с поста главы НАК

Витренко объяснил, почему хочет уволить своего экс-соратника Коболева с поста главы НАК
izvestia.kiev.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from izvestia.kiev.ua Daily Mail and Mail on Sunday newspapers.

Energy ukraineCompany supervisory boardMarketing ventraஆற்றல் உக்ரைன்நிறுவனம் மேற்பார்வை பலகை

Tremendous success for MedinCell s €30 million capital increase for qualified investors

Tremendous success for MedinCell s €30 million capital increase for qualified investors Strong support from French and international leading shareholders and investors Regulatory News: MedinCell (Paris:MEDCL) (FR0004065605 MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the Company ), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the Offering 1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners. Buoyed by very strong interest during the book building process, the capital increase was priced at a modest discount of 8% to the closing price of the Company s shares on the Euronext Paris regulated market on February 10, 2021 and accounted for 10,9% of the Company s share capital through the issuance of 2.414.2

United statesUnited kingdomJaime arangoChristophe douatMathilde bohin louis victor delouvrierNicolas merigeauDavid heuzCompany management boardEuropean parliamentGarnier coFinancial servicesCompany supervisory boardWhile the companyEuropean union withdrawalJoint global coordinatorsEuronext paris

MedinCell Announces a Capital Increase of a c €30 Million

MedinCell Announces a Capital Increase of a c.€30 Million Portefeuille au 31 janvier 2021 (Graphic: Business Wire) This press release is not intended for publication or distribution in the United States, Canada, Japan or Australia. MedinCell (FR0004065605 MEDCL) (Paris:MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the Company ), announces today a capital increase of €c.30 million through an offering to qualified investors, both French and international, by way of an accelerated bookbuilding process (the Offering Reasons for the Offering We have been in the spotlight recently because of the very successful Phase 3 trial of the first product based on our BEPO

United statesFrance generalUnited kingdomChristophe douatMathilde bohin louis victor delouvrierNicolas merigeauDavid heuzCompany management boardGarnier coEuropean parliamentFinancial servicesCompany supervisory boardWhile the companyEuropean union withdrawalRegulatory newsBusiness wire

Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris

Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris Offer oversubscribed 4 times, with global demand totaling €28.1 million Capital increase of approximately €8 million, after full exercise of the Extension Clause Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE) Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth market in Paris. Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says: I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who have chosen to accompany us

United statesFrance generalUnited kingdomPherecydes pharmaPhilippe rousseauBpifrance entrepriseKostenloser wertpapierhandelNicolas merigeauDusan oresanskyEntreprise innovanteRegulations of the french market authority autoritEuropean parliamentEarly access programFinancial servicesCompany supervisory boardProspectus directive of the european union